Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
October 7th 2024Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis
October 7th 2024Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.
Adult vs Pediatric Plaque Psoriasis Treatment Challenges
September 30th 2024Panelists discuss how limited treatment options, safety concerns, adherence issues, and the lack of long-term data pose significant challenges in effectively managing pediatric vs adult plaque psoriasis, highlighting the need for more research and tailored approaches for this patient population.
Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis
September 30th 2024Karan Lal, DO, and Helen T Shin, MD, discuss how early diagnosis of pediatric plaque psoriasis significantly improves management strategies and enhances long-term outcomes by allowing for timely intervention and personalized treatment plans.
Diagnostic Challenges in the Management of Pediatric Plaque Psoriasis
September 23rd 2024Karan Lal, DO, and Helen T Shin, MD, discuss how diagnostic challenges in pediatric plaque psoriasis, such as its similarity to other skin conditions and potential underreporting, can complicate timely identification and appropriate management of the disease in children.